Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG

• Status: Completed
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

Study Objectives:

1. To prove that the use of GnHR agonist for final oocyte maturation results in a higher percentage of mature oocytes than the use of hCG.

2. To show an advantage in women's satisfaction in the proposed protocol versus the standard antagonist protocol In the study group women will receive GnRH agonist for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU. Blood samples for BHCG, progesterone and estradiol will be obtained 14 days after embryo transfer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HaEmek Medical Center, Israel
• Treatments: Deslorelin; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• patients who are eligible for in vitro fertilization using an antagonist protocol

Exclusion Criteria:

• patients diagnosed with hypogonadotrophic hypogonadism, sensitivity to any of the drugs used in the study A patient enrolled in the study who, as a result of ovarian stimulation, responds in a way that puts her in risk of developing ovarian hyperstimulation, will be ultimately excluded from the study.